Trial reportHuman psychopharmacology2026
Assessment of the Efficacy of Quercetin in Adult Patients With Autism Spectrum Disorder: A Randomized, Triple-Blind, Placebo-Controlled Trial.
Trial report in Human psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis randomized, triple-blind, placebo-controlled clinical trial evaluated the efficacy and safety of quercetin in adults with autism spectrum disorder (ASD).
methodsFifty-two adults with ASD were randomly assigned to receive either quercetin or placebo for 60 days. Outcomes included the Social Responsiveness Scale (SRS), WHO Quality of Life (WHOQOL) domains, and other clinical measures assessed at baseline, 30 days, and 60 days.
resultsBaseline demographic characteristics and comorbid conditions were comparable between groups. The quercetin group showed a significant within-group reduction in SRS scores over time (p = 0.010), whereas the placebo group showed no significant change (p = 0.655). However, between-group differences in SRS change were not statistically significant. At week 8, the physical health domain of WHOQOL improved more in the quercetin group at the unadjusted level (p = 0.044), but this was not significant after adjustment (p = 0.082). The environmental health domain showed a borderline difference favoring quercetin (adjusted p = 0.053).
conclusionQuercetin supplementation showed potential benefits in select social quality of life and social domain responsiveness in participants with ASD. Larger, well-designed trials are needed to confirm its clinical effectiveness.
trial registrationIRCT20241214064050N1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.